ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。

AUPH Aurinia Pharmaceuticals Inc

4.9001
0.0301 (0.62%)
2024年4月27日 - 終了
15分遅延
名称 銘柄コード 市場 種別
Aurinia Pharmaceuticals Inc AUPH NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
0.0301 0.62% 4.9001 08:43:37
始値 安値 高値 終値 前日終値
4.89 4.86 5.01 4.91 4.87
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/1623:48BWUPDATE: New Aurinia Presentation Details at the 2024 Bloom..
2024/4/1519:00BWAurinia Pharmaceuticals to Release First Quarter Financial..
2024/4/0919:00BWAurinia Will Attend 2024 Bloom Burton & Co. Healthcare..
2024/3/0806:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/3/0806:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/3/0806:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/3/0806:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/3/0106:10EDGAR2Form 8-K - Current report
2024/2/2922:30BWAurinia Receives Exemptive Relief from Canadian Securities..
2024/2/2722:30BWAurinia to Participate in Upcoming Investor Healthcare..
2024/2/2306:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/2306:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/2306:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/2306:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/2306:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/2306:19EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
2024/2/1520:16EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2024/2/1520:06EDGAR2Form 8-K - Current report
2024/2/1520:00BWAurinia Discloses 2023 Year-End Financial and Operational..
2024/2/1505:27EDGAR2Form SC 13G - Statement of acquisition of beneficial..
2024/2/0522:30BWAurinia Pharmaceuticals to Release 2023 Fourth Quarter and..
2024/1/0520:02EDGAR2Form 8-K - Current report
2024/1/0520:00BWAurinia Provides Preliminary Unaudited Fourth Quarter and..
2023/12/2020:00BWAurinia Submits IND Application to US Food & Drug..
2023/11/1320:00BWAurinia Pharmaceuticals Announces Collaboration Partner..
2023/11/0800:30BWAurinia Presents Breadth of Data from AURORA Clinical..
2023/11/0307:00BWAurinia Presents Breadth of Data at ASN 2023 Demonstrating..
2023/11/0219:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/0219:01EDGAR2Form 8-K - Current report
2023/11/0219:00BWAurinia Pharmaceuticals Reports Third Quarter and Nine..
2023/10/2704:00BWAurinia Response in Support of 2023 Updated EULAR..
2023/10/1923:31BWCORRECTING and REPLACING Aurinia Pharmaceuticals to Release..
2023/10/1919:00BWAurinia Pharmaceuticals to Release Third Quarter Financial..
2023/10/1401:00BWAurinia Pharmaceuticals Announces Presentations at American..
2023/9/2305:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/9/2205:06EDGAR2Form 8-K - Current report
2023/9/2119:00BWAurinia Board of Directors Appoints Dr. Robert T. Foster as..
2023/8/2205:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/8/2205:11EDGAR2Form 8-K - Current report
2023/8/2119:00BWAurinia Appoints Two New Board Directors with Deep..
2023/8/0319:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/8/0319:03EDGAR2Form 8-K - Current report
2023/8/0319:00BWAurinia Pharmaceuticals Reports Second Quarter and Six..
2023/7/2019:00BWAurinia Pharmaceuticals to Release Second Quarter Financial..
2023/7/2001:05BWLong Term Phase 3 Data Published in Arthritis & Rheumatology..
2023/7/0621:33EDGAR2Form PX14A6G - Notice of exempt solicitation submitted by..
2023/7/0319:06EDGAR2Form 8-K - Current report
2023/6/3005:05BWAurinia Board of Directors Announces Exploration of..
2023/6/2022:00BWAurinia Showcases Three Oral Presentations for LUPKYNIS®..
2023/6/0122:00BWLUPKYNIS® (voclosporin) Achieved Significantly Higher Renal..

最近閲覧した銘柄

Delayed Upgrade Clock